Merck, Daiichi post trial data for lung cancer drug (NYSE:MRK) | Seeking Alpha
Merck and Daiichi Sankyo announced interim Phase 2 trial results for lung cancer treatment ifinatamab deruxtecan (I-DXd), showing objective response rates of ~55% and ~26% at 12 mg/kg and 8 mg/kg doses, respectively. The 12 mg/kg dose led to 23 partial responses, while the 8 mg/kg dose resulted in one complete and 11 partial responses. Median overall survival was 11.8 months and 9.4 months for the respective doses. Preliminary intracranial ORRs were 50.0% and 66.7% across the two dose groups. Adverse events led to 17% and 6.5% dropouts for the respective doses. The 12 mg/kg dose is selected for the trial's expansion part, with data to be presented at the World Conference on Lung Cancer in San Diego.
Reference News
Merck and Daiichi Sankyo announced interim Phase 2 trial results for lung cancer treatment ifinatamab deruxtecan (I-DXd), showing objective response rates of ~55% and ~26% at 12 mg/kg and 8 mg/kg doses, respectively. The 12 mg/kg dose led to 23 partial responses, while the 8 mg/kg dose resulted in one complete and 11 partial responses. Median overall survival was 11.8 months and 9.4 months for the respective doses. Preliminary intracranial ORRs were 50.0% and 66.7% across the two dose groups. Adverse events led to 17% and 6.5% dropouts for the respective doses. The 12 mg/kg dose is selected for the trial's expansion part, with data to be presented at the World Conference on Lung Cancer in San Diego.